d1,s3,s4-transitioning to green propellants and the potential impact on generic drugs
Published 2 years ago • 65 plays • Length 5:00
Download video MP4
Download video MP3
Similar videos
-
11:47
d1 s1,s4-industry perspective on generic prod develop challenges & res priorities next 5 yr - iii
-
4:56
d1,s3,s3-understanding endogenous nitrosation -vs- impact of nitrosamine impurities in drug products
-
9:38
d1,s1,s3-industry perspective on generic prod develop challenges & res priorities next 5 yr - ii
-
15:39
office of generic drugs keynote (1of39) complex generics 2018
-
14:37
d1,s1,s2-industry perspective on generic prod develop challenges & res priorities next 5 yr - i
-
15:36
d1,s1,s5-advancing development of complex generics to improve patient access to medicines
-
4:53
d1,s3,s1 -need biorelevant/biopredictive ivr methods for lai, inhalation, other complex generics
-
19:10
product-specific guidances for complex generic drugs
-
7:53
d2,s5,s1-current challenges to complex generic drug development under divergent global regulations
-
15:59
overview of current science-based regulatory standards (21of39) complex generics 2018
-
25:59
fda’s inactive ingredient database (iid) (3of35) complex generics – sep. 25-26, 2019
-
19:07
be approaches for long acting drug products (14of35) complex generics – sep. 25-26, 2019
-
10:38
d1,s4a,s3-exploration of forward-looking ideas for inhibiting nitrosamine formation in drug products
-
20:30
quality for transdermal delivery systems (8of35) complex generic drugs – sep. 25-26, 2019
-
19:08
generic topical and transdermal products (5of35) complex generics– sep. 25-26, 2019
-
30:26
in vitro and in vivo abuse deterrence evaluation of generic opioids (30of39) complex generics 2018
-
20:14
generic drug product quality assessment (22of27) generic drugs forum 2018
-
19:35
questions and panel discussion (9of39) complex generics 2018
-
30:23
pre-anda program update (2of35) complex generics– sep. 25-26, 2019
Clip.africa.com - Privacy-policy